Quantitative analysis of nailfold capillary abnormalities in patients with connective tissue diseases

International Journal of Dermatology

Volumn 38, Issue 10, 1999, Pages 757-764

  Ohtsuka, Tsutomu ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; NAIL DISEASE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SKIN CAPILLARY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

CAPILLARIES; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; HUMANS; MICROSCOPY; NAILS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 0032743162     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00773.x     Document Type: Article

References (51)

1. Redisch W, Messina EJ, Hughes G, McEwen C. Capillaroscopic observations in rheumatic diseases. Ann Rheum Dis 1970; 29: 244-253.
2. Rouen LR, Terry EN, Doft BH, et al. Classifications and measurement of surface microvessels in man. Microvasc Res 1972; 4: 285-292.
3. Maricq HR. Widefield capillary microscopy. Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 1981; 24: 1159-1165.
4. Ubbink DT, Janssen HA, Schreurs MM, Jacobs MJ. Capillary microscopy is a diagnostic aid in patients with acral ischemia. Angiology 1995; 46: 59-64.
5. Lee P, Leung FY-K, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol 1983; 10: 930-938.
6. Schmidt K-U, Mensing H. Are nailfold capillary changes indicators of organ involvement in progressive systemic sclerosis? Dermatologica 1988; 176: 18-21.
7. Lefford F, Edwards JCW. Nailfold capillary microscopy in connective tissue diseases: a quantitative morphological analysis. Ann Rheum Dis 1986; 45: 741-749.
8. Statham BN, Rowell NR. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Derm Venereol (Stockh) 1986; 66: 139-143.
9. Studer A, Hunziker T, Lutolf O, et al. Quantitative nailfold capillary microscopy in cutaneous and systemic lupus erythematosus and localized and systemic scleroderma. J Am Acad Dermatol 1991; 24: 941-945.
10. Ohtsuka T, Ishikawa H. Statistical definition of nailfold capillary pattern in patients with systemic sclerosis. Dermatology 1994; 188: 286-298.
11. Michoud E, Poensin D, Carpentier PH. Digitized nailfold capillaroscopy. Vasa 1994; 23: 35-42.
12. Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. Ann Rheum Dis 1996; 55: 507-512.
13. Lachenbruch PA. Discriminant Analysis. New York: Macmillan, 1975.
14. Gnanadesikan R. Methods for Statistical Data Analysis of Multivariate Observations. New York: Wiley, 1977.
15. Kendall M. Multivariate Analysis, 2nd edn. High Wycombe: Charles Griffin, 1982.
16. Tanaka Y, Tarumizu T, Wakimoto K. Handbook of Statistical Analysis Using Personal Computer. Part 2: Multivariate Analysis. Tokyo: Kyoritsu Publishing, 1984.
17. Kenik JG, Maricq HR, Bole GG. Blind evaluation of the diagnostic specificity of nailfold capillary abnormalities capillary microscopy in the connective tissue diseases. Arthritis Rheum 1981; 24: 885-891.
18. Harper FE, Maricq HR, Turner RE, et al. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 1982; 72: 883-888.
19. Maricq HR. The microcirculation in scleroderma and allied disease. Adv Microcirc 1982; 10: 17-23.
20. Ohtsuka T, Yamakage A, Tamura T. Image analysis of nail fold capillaries in patients with Raynaud's phenomenon. Cutis 1995; 56: 215-218.
21. Borg EJ, Piersma-Wichers G, Smith AJ, et al. Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 1994; 24: 40-47.
22. Ohtsuka T, Yamakage A, Tamura T. Image analysis of nail fold capillaries in patients with undifferentiated connective tissue syndromes. J Dermatol 1995; 22: 921-925.
23. Vayssairat M, Baudot N, Gaitz JP. Raynaud's phenomenon together with antinuclear antibodies: a common subject of incomplete connective tissue disease. J Am Acad Dermatol 1995; 32: 747-749.
24. Mannarino E, Pasqualini L, Fedeli F, et al. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon. Angiology 1994; 45: 37-42.
25. Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon: long-term follow-up study of 73 cases. Am J Med 1987; 83: 494-498.
26. Fitzgerald O, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988; 84: 718-726.
27. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980; 23: 183-189.
28. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006.
29. Maricq HR, Harper FE, Khan MM, et al. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195-205.
30. Zufferey P, Depairon M, Chamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study. Clin Rheumatol 1992; 11: 536-541.
31. Luggen M, Belhorn L, Evans T, et al. The evolution of Raynaud's phenomenon: a long-term prospective study. J Rheumatol 1995; 22: 2226-2232.
32. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue disease. Clin Rheumatol 1996; 15: 148-153.
33. Ohtsuka T, Tamura T, Yamakage A, Yamazaki S. Predictive value of nailfold capillary abnormality in patients with connective tissue disease. Br J Dermatol 1998; 139: 815-821.
34. Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as an indicator of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976; 61: 862-870.
35. Maricq HR, Weinlich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population: a preliminary study by questionnaire. J Chronic Dis 1986; 39: 423-427.
36. Danieli MG, Fraticelli P, Salvi A, et al. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 1998; 17: 195-201.
37. Williams HJ, Alarcon GS, Neuner R, et al. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. J Rheumatol 1998; 25: 261-268.
38. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158: 595-600.
39. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 131: 196-203.
40. Ohtsuka T, Hasegawa A, Nakano A, et al. Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis. Int J Dermatol 1997; 36: 116-122.
41. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65-74.
42. Sackner MA, Akgun N, Kinbel P, Lewis D. The pathophysiology of scleroderma involving the heart and respiratory system. Ann Intern Med 1964; 60: 611-630.
43. Groen H, Wichers G, Borg EJ. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. Am J Med 1990; 89: 34-41.
44. Houtman PM, Kallenberg CGM, Wounda A, The TH. Decreased nailfold capillary density in Raynaud's phenomenon: a reflection of immunologically mediated local and systemic vascular disease? Ann Rheum Dis 1985; 44: 603-609.
45. Owens GR, Fino GJ, Herbert DL, et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983; 84: 546-550.
46. Simeon CP, Armadans L, Fonollosa V, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 723-728.
47. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997; 24: 81-85.
48. Scher RK, Tom DWK, Lally EV, Bogaars HA. The clinical significance of periodic acid-Schiff-positive deposits in cuticle-proximal nail fold biopsy specimens. Arch Dermatol 1985; 121: 1406-1409.
49. Freemont AJ, Hoyland J, Fielding P, et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 1992; 126: 561-568.
50. Rolla G, Colagrande P, Brussino L, et al. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension. Lancet 1998; 351: 1491-1492.
51. Salojin KV, Le Tonqueze M, Saraux A, et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997; 102: 178-185.